PL2331118T3 - Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka - Google Patents

Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Info

Publication number: PL2331118T3
Authority: PL; Poland
Prior art keywords: cancer; gbm; glioma; tumor; types
Prior art date: 2008-10-01

Application number

PL09778749T

Other languages

English (en)

Inventor

Oliver Schoor

Norbert Hilf

Toni Weinschenk

Claudia Trautwein

Steffen Walter

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2009-09-28

Publication date

2017-05-31

2009-09-28 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2017-05-31 Publication of PL2331118T3 publication Critical patent/PL2331118T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)

PL09778749T 2008-10-01 2009-09-28 Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka PL2331118T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP20080017305 EP2172211B1 (en)	2008-10-01	2008-10-01	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US10597008P	2008-10-16	2008-10-16
EP09778749.3A EP2331118B1 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Publications (1)

Publication Number	Publication Date
PL2331118T3 true PL2331118T3 (pl)	2017-05-31

Family

ID=40342382

Family Applications (12)

Application Number	Title	Priority Date	Filing Date
PL08017305T PL2172211T3 (pl)	2008-10-01	2008-10-01	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL08017921T PL2172212T3 (pl)	2008-10-01	2008-10-13	Nowatorska immunoterapia przeciwko szeregowi guzów włączając guzy neuronowe i guzy mózgu
PL16179163T PL3106175T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179192T PL3120869T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179226T PL3120870T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16165070T PL3069728T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179169T PL3132801T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL09778750.1T PL2341927T3 (pl)	2008-10-01	2009-09-28	Kompozycja obejmująca peptydy związane z nowotworem i szczepionka do leczenia glejaka i innych nowotworów
PL16179174T PL3120868T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179241T PL3111952T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179214T PL3124043T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL09778749T PL2331118T3 (pl)	2008-10-01	2009-09-28	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Family Applications Before (11)

Application Number	Title	Priority Date	Filing Date
PL08017305T PL2172211T3 (pl)	2008-10-01	2008-10-01	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL08017921T PL2172212T3 (pl)	2008-10-01	2008-10-13	Nowatorska immunoterapia przeciwko szeregowi guzów włączając guzy neuronowe i guzy mózgu
PL16179163T PL3106175T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179192T PL3120869T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179226T PL3120870T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16165070T PL3069728T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179169T PL3132801T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL09778750.1T PL2341927T3 (pl)	2008-10-01	2009-09-28	Kompozycja obejmująca peptydy związane z nowotworem i szczepionka do leczenia glejaka i innych nowotworów
PL16179174T PL3120868T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179241T PL3111952T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179214T PL3124043T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu

Country Status (24)

Country	Link
US (19)	US8119139B2 (pl)
EP (12)	EP2172211B1 (pl)
JP (10)	JP5855940B2 (pl)
KR (6)	KR101687840B1 (pl)
CN (3)	CN106986919A (pl)
AU (2)	AU2009300088B2 (pl)
BR (2)	BRPI0920759A2 (pl)
CA (9)	CA2739384C (pl)
CY (11)	CY1116302T1 (pl)
DK (12)	DK2172211T3 (pl)
EA (3)	EA032437B1 (pl)
ES (12)	ES2536465T3 (pl)
HR (12)	HRP20170115T1 (pl)
HU (11)	HUE031030T2 (pl)
LT (10)	LT2172212T (pl)
MX (3)	MX2011003540A (pl)
NZ (4)	NZ591882A (pl)
PL (12)	PL2172211T3 (pl)
PT (12)	PT2172211E (pl)
RS (12)	RS53782B1 (pl)
SI (12)	SI2172211T1 (pl)
TR (2)	TR201900809T4 (pl)
UA (3)	UA103202C2 (pl)
WO (2)	WO2010037513A1 (pl)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006023598A2 (en)	2004-08-19	2006-03-02	University Of Maryland, Baltimore	Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en)	2004-09-21	2006-03-30	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
DK2183361T3 (en) *	2007-07-27	2015-07-27	Immatics Biotechnologies Gmbh	Novel immunotherapy against brain tumors
ATE462442T1 (de) *	2008-04-30	2010-04-15	Immatics Biotechnologies Gmbh	Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
PL2119726T5 (pl)	2008-05-14	2018-04-30	Immatics Biotechnologies Gmbh	Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
ES2536465T3 (es)	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) *	2009-12-15	2013-03-19	Theravac Pharmaceuticals Ab	Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) *	2010-03-19	2016-11-10	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
MX353165B (es) *	2010-08-24	2017-12-20	Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star	Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2012075490A2 (en) *	2010-12-03	2012-06-07	Duke University	Anti-podoplanin antibodies and methods of use
CA2821582A1 (en) *	2010-12-14	2012-06-21	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US20140154269A1 (en) *	2011-04-26	2014-06-05	The Methodist Hospital Research Institute	Targeted nanovectors and their use for treatment of brain tumors
CA2847698C (en)	2011-09-14	2020-09-01	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en)	2011-12-02	2012-01-11	Immodulon Therapeutics Ltd	Cancer therapy
KR20220137154A (ko)	2012-01-20	2022-10-11	데니스 엠. 브라운	다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
EP4321218A3 (en)	2012-05-16	2024-04-24	Stemline Therapeutics, Inc.	Cancer stem cell targeted cancer vaccines
CN103566377A (zh) *	2012-07-18	2014-02-12	上海博笛生物科技有限公司	癌症的靶向免疫治疗
TWI777194B (zh) *	2013-08-05	2022-09-11	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
ES3010561T3 (en) *	2013-08-05	2025-04-03	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors, such as lung cancer including nsclc
MX2019013161A (es) *	2013-11-04	2020-02-03	Immatics Biotechnologies Gmbh	Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) *	2013-12-04	2017-07-21	苏州中赢医疗科技有限公司	一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en)	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
EP3092049A1 (en)	2014-01-08	2016-11-16	Flodesign Sonics Inc.	Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) *	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
SMT202000355T1 (it)	2014-04-25	2020-09-10	Bluebird Bio Inc	Metodi migliorati per produrre terapie con cellule adottive
PL3689899T3 (pl)	2014-04-25	2022-01-31	2Seventy Bio, Inc.	Chimeryczne receptory antygenowe promotora mnd
JP6613526B2 (ja) *	2014-05-28	2019-12-04	学校法人東京女子医科大学	膠芽腫の予測方法
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
EP3151672B1 (en) *	2014-06-06	2020-11-04	Bluebird Bio, Inc.	Improved t cell compositions
JP6366379B2 (ja) *	2014-06-20	2018-08-01	キヤノン株式会社	被検体情報取得装置
CA2956002C (en)	2014-07-24	2023-06-27	Bluebird Bio, Inc.	Bcma chimeric antigen receptors
MX386458B (es) *	2014-11-06	2025-03-18	Ose Immunotherapeutics	Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.
JP6671370B2 (ja)	2014-12-12	2020-03-25	ブルーバードバイオ，インコーポレイテッド	Ｂｃｍａキメラ抗原受容体
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211327T1 (hr)	2014-12-23	2022-01-21	Immatics Biotechnologies Gmbh	Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
TWI755157B (zh)	2015-03-17	2022-02-11	德商英麥提克生物技術股份有限公司	用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
JP6985153B2 (ja) *	2015-05-06	2021-12-22	イマティクスバイオテクノロジーズゲーエムベーハー	結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
WO2016200787A2 (en)	2015-06-09	2016-12-15	The Board Of Regents Of The University Of Oklahoma	Compositions and treatments for haemophilus influenzae
MX389834B (es)	2015-06-24	2025-03-20	Immodulon Therapeutics Ltd	Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA42294B1 (fr)	2015-07-01	2020-11-30	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
CR20170579A (es) *	2015-07-06	2018-05-25	Immatics Biotechnologies Gmbh	Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040885A1 (en)	2015-09-03	2017-03-09	The Board Of Regents Of The University Of Oklahoma	Peptide inhibitors of clostridium difficile tcdb toxin
WO2017070237A1 (en)	2015-10-19	2017-04-27	University Of Maryland, Baltimore	Methods for generating engineered human primary blood dendritic cell lines
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
GB201521746D0 (en) *	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) *	2015-12-11	2023-01-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides for use in immunotherapy against several types of cancer
CA3008641A1 (en)	2015-12-16	2017-06-22	Gritstone Oncology, Inc.	Neoantigen identification, manufacture, and use
US10604759B2 (en)	2016-01-15	2020-03-31	City Of Hope	Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
CN109620949A (zh) *	2016-03-13	2019-04-16	曹帅	一种用于治疗骨癌的药物组合物
PL3430037T3 (pl)	2016-03-16	2022-12-19	Immatics Biotechnologies Gmbh	Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
GB201604494D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
SG10202110335PA (en) *	2016-04-06	2021-10-28	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
WO2017194170A1 (en) *	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko)	2016-06-30	2018-07-25	영남대학교 산학협력단	아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
PT3518948T (pt) *	2016-10-03	2023-07-17	Ottawa Hospital Res Inst	Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
JP7093346B2 (ja)	2016-11-04	2022-06-29	２セブンティバイオインコーポレイテッド	抗ｂｃｍａｃａｒｔ細胞組成物
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	짝짓기가 향상된 t 세포 수용체
CA3043630A1 (en)	2016-12-22	2018-06-28	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
EP4032911A1 (en)	2017-01-06	2022-07-27	Eutilex Co., Ltd.	Anti-human 4-1bb antibodies and use thereof
GB201702863D0 (en) *	2017-02-22	2017-04-05	Evox Therapeutics Ltd	Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) *	2017-02-28	2018-08-30	Lyten, Inc.	Mixed allotrope particulate carbon films and carbon fiber mats
TW201907937A (zh) *	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
CN107034305A (zh) *	2017-06-19	2017-08-11	上海市第十人民医院	恶性胶质瘤的一种诊断标志物
CN107058596A (zh) *	2017-06-19	2017-08-18	上海市第十人民医院	一种与恶性胶质瘤诊断相关的标志物及其应用
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20200090855A (ko)	2017-11-22	2020-07-29	그릿스톤 온콜로지, 인코포레이티드	신생항원에 대한 접합 에피토프 제시 감소
CN114900773A (zh)	2017-12-14	2022-08-12	弗洛设计声能学公司	声泳系统及其操作方法、控制声换能器及声学系统的方法
CN111344402A (zh) *	2017-12-14	2020-06-26	Ezy生物科技有限公司	受试者特异性肿瘤抑制细胞及其用途
FI3773689T3 (fi) *	2018-04-11	2023-01-31		Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
CN108715832B (zh) *	2018-06-01	2020-11-10	段海峰	一种抑制肿瘤生长的间充质干细胞及制备方法和应用
CN120843603A (zh)	2018-07-11	2025-10-28	布里格姆妇女医院	用于跨血脑屏障递送试剂的方法和组合物
WO2020110154A1 (en) *	2018-11-30	2020-06-04	Bharat Biotech International Limited	A chimeric therapeutic vaccine
RU2706554C1 (ru) *	2018-12-13	2019-11-19	Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ	Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) *	2019-02-22	2021-09-17	上海尚泰生物技术有限公司	一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
CN113645997B (zh)	2019-03-29	2024-12-17	英特维特国际股份有限公司	在液体组合物中对活的柔膜菌纲细菌的稳定化
WO2020206385A1 (en) *	2019-04-05	2020-10-08	Earli Inc.	Improved methods and compositions for synthetic biomarkers
JP7150289B2 (ja)	2019-05-28	2022-10-11	ペイジ．エーアイインコーポレイテッド	デジタル病理学のための処理された画像に関するスライドを調製するために画像を処理するためのシステムおよび方法
MX2021014525A (es)	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
CN110579457B (zh) *	2019-09-20	2021-11-02	郑州大学第一附属医院	波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) *	2019-11-18	2022-06-24	杨小骏	一种抑制胶质瘤的短肽及其应用
JP2023510784A (ja) *	2020-01-10	2023-03-15	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	脳腫瘍を処置するための血液脳関門を横断する免疫療法剤を送達するための方法および組成物
WO2021173193A1 (en) *	2020-02-24	2021-09-02	The Regents Of The University Of California	Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) *	2020-02-28	2024-01-19	无锡派列博生物医药科技有限公司	肿瘤免疫增强剂及其制法和应用
CN111333698B (zh) *	2020-03-18	2021-11-23	北京鼎成肽源生物技术有限公司	一种乳腺癌靶标抗原组合、乳腺癌靶标抗原组合刺激培养的ctl细胞及其应用
EP4127188A4 (en)	2020-03-31	2024-08-21	Walking Fish Therapeutics	MODIFIED B CELLS AND METHODS OF USE THEREOF
AU2021249123A1 (en) *	2020-03-31	2022-10-27	Walking Fish Therapeutics	Modified B cells and methods of use thereof
CN116096405A (zh)	2020-05-12	2023-05-09	Cue生物制药股份有限公司	多聚体t细胞调节多肽及其使用方法
JP2023541108A (ja)	2020-08-06	2023-09-28	グリットストーンバイオインコーポレイテッド	マルチエピトープワクチンカセット
KR102711471B1 (ko)	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022047248A1 (en) *	2020-08-28	2022-03-03	Torigen Pharmaceuticals, Inc.	Immune memory enhanced preparations and uses thereof
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
EP4305211A1 (en) *	2021-03-09	2024-01-17	BostonGene Corporation	Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) *	2022-03-30	2025-07-24	Iogenetics, Llc	Tumor-associated antigens in brain tumors
PL441229A1 (pl) *	2022-05-19	2023-11-20	Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk	Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
CN120272531B (zh) *	2025-06-10	2025-08-19	鼐济医药科技(杭州)有限公司	一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da)	1978-12-22	1997-04-14	Biogen Inc	Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) *	1988-04-12	1994-08-16	Massachusetts Institute Of Technology	DNA encoding nestin protein
KR100235089B1 (en)	1992-05-14	1999-12-15	Mitsui Chemicals Inc	Ptp or blister packaging articles and packaging material therefor
GB2267257A (en)	1992-05-14	1993-12-01	Ford Motor Co	A vehicle load compartment liner.
ES2108460T3 (es)	1993-06-03	1997-12-16	Therapeutic Antibodies Inc	Fragmentos de anticuerpos en terapeutica.
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en)	1996-01-17	2010-08-10	Imperial College Innovations Limited	Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) *	1996-04-24	1997-07-13	Akzo Nobel Nv	Peptides suitable for use in immunosuppressive therapy
WO1998003197A1 (en) *	1996-07-22	1998-01-29	The Rockefeller University	Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU6240798A (en)	1997-01-15	1998-08-07	Zymogenetics Inc.	Zppar6, human tailless nuclear hormone receptor (tlx receptor)
CA2243984A1 (en) *	1997-02-13	1998-08-20	Smithkline Beecham P.L.C.	Neural cell adhesion molecule splicing variants
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU750358B2 (en) *	1997-12-02	2002-07-18	Medarex, Inc.	Cells expressing anti-Fc receptor binding components
US7258860B2 (en) *	1998-03-18	2007-08-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
WO1999055380A1 (en) *	1998-04-27	1999-11-04	Pacific Northwest Cancer Foundation	Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
US20030082586A1 (en) *	1999-06-29	2003-05-01	Millennium Pharmaceuticals, Inc.	Antibodies having diagnostic, preventive, therapeutic, and other uses
WO2001055448A1 (en) *	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
US20020132753A1 (en) *	2000-01-31	2002-09-19	Rosen Craig A.	Nucleic acids, proteins, and antibodies
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (en)	2000-03-27	2001-10-04	Technion Research And Development Foundation Ltd.	Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
AU2001279581A1 (en) *	2000-09-06	2002-03-22	Friederike Muller	Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2295575A3 (en) *	2000-12-04	2011-07-06	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) *	2000-12-08	2004-01-14	Oxford GlycoSciences (UK) Limited	Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) *	2001-03-19	2002-09-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) *	2001-11-30	2003-05-30	Christopher Gillberg	Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en)	2001-12-21	2003-07-08	Kloeckner Pentaplast Of America, Inc.	Three part high moisture barrier for packages
US7892559B2 (en) *	2002-01-30	2011-02-22	Survac Aps	Survivin-derived peptides and use thereof
US6992176B2 (en) *	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en)	2002-02-20	2006-04-26	Dyax Corp	MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004015390A2 (en) *	2002-08-09	2004-02-19	Applera Corporation	Lung cancer target proteins and use thereof
JP4721633B2 (ja) *	2002-10-11	2011-07-13	財団法人癌研究会	血小板凝集促進活性を有する物質
CA2511927A1 (en) *	2002-12-27	2004-08-12	Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd.	Method of preparing a vaccine and anti-tumor vaccines
CA2520452A1 (en)	2003-04-04	2004-10-21	Pharmacyclics, Inc.	Sapphyrins and uses thereof
US7273980B2 (en)	2004-01-13	2007-09-25	Wardle Scott A	Position and velocity transducer using a phonograph disc and turntable
WO2005071075A1 (ja) *	2004-01-23	2005-08-04	Green Peptide Co., Ltd.	上皮細胞増殖因子受容体（egfr）由来ペプチド
DE102004026135A1 (de)	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) *	2004-08-27	2006-03-09	Northeastern University	Comprehensive characterization of complex proteins at trace levels
DE602004019215D1 (de) *	2004-10-02	2009-03-12	Immatics Biotechnologies Gmbh	Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
JP5087925B2 (ja) *	2004-12-07	2012-12-05	東レ株式会社	新規癌抗原ペプチド及びその用途
KR100809410B1 (ko) *	2005-07-06	2008-03-05	주식회사 브레인가드	줄기세포 분화 유도용 조성물 및 그의 용도
PT1760089E (pt) *	2005-09-05	2009-10-19	Immatics Biotechnologies Gmbh	Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
DK1806359T3 (da)	2005-09-05	2010-06-14	Immatics Biotechnologies Gmbh	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
EP1938104A2 (en)	2005-10-17	2008-07-02	Institute for Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) *	2005-12-06	2007-10-25	Keller Lorraine H	Immunogens in cancer stem cells
WO2007072494A1 (en)	2005-12-23	2007-06-28	Naik Praful Ramchandra	Metallized packaging blister container
CA2665816C (en) *	2006-09-21	2016-07-12	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
CA2700573C (en) *	2006-09-26	2016-11-22	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) *	2007-03-06	2008-09-12	Barry G. Arnason	Methods and compositions involving polymeric immunoglobulin fusion proteins
US8747855B2 (en) *	2008-04-09	2014-06-10	Technion Research & Development Foundation Limited	Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) *	2008-04-24	2012-09-20	이매틱스 바이오테크놀로지스 게엠베하	백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ATE462442T1 (de) *	2008-04-30	2010-04-15	Immatics Biotechnologies Gmbh	Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
ES2536465T3 (es)	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en)	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN106661126B (zh) *	2014-05-28	2021-12-10	诺诺公司	TAT-NR2B9c的氯盐
BR112018070873A2 (pt)	2016-04-21	2019-02-05	Immatics Biotechnologies Gmbh	imunoterapia contra melanoma e outros cânceres
CN111315769A (zh) *	2017-09-06	2020-06-19	加州理工学院	信号传导和抗原呈递双功能受体(sabr)

2008
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
2009
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko active Active
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja active Active
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
2021
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en active Active

Also Published As

Publication number	Publication date
SI3106175T1 (sl)	2020-08-31
CA2936887A1 (en)	2010-04-08
HRP20170115T1 (hr)	2017-03-24
HUE049367T2 (hu)	2020-09-28
CY1121098T1 (el)	2019-12-11
EP3124043B1 (en)	2020-04-29
CA2936887C (en)	2019-11-12
JP6214066B2 (ja)	2017-10-18
US10046037B2 (en)	2018-08-14
HUE050428T2 (hu)	2020-12-28
ES2607460T3 (es)	2017-03-31
HRP20201015T8 (hr)	2022-01-21
AU2009300088A1 (en)	2010-04-08
EP3106175B1 (en)	2020-04-01
HRP20190202T1 (hr)	2019-03-22
KR101883426B1 (ko)	2018-07-31
RS55043B1 (sr)	2016-12-30
RS55543B1 (sr)	2017-05-31
LT2172212T (lt)	2016-11-10
DK3106175T3 (da)	2020-06-22
DK3120869T3 (da)	2020-08-10
CA2936982C (en)	2019-12-03
JP2012504563A (ja)	2012-02-23
HRP20200110T1 (hr)	2020-05-15
EP3111952B1 (en)	2018-10-31
HK1159526A1 (zh)	2012-08-03
CN102170901B (zh)	2015-01-07
US20150125478A1 (en)	2015-05-07
BRPI0920791B8 (pt)	2022-02-15
SI3069728T1 (sl)	2019-03-29
DK2172211T3 (en)	2015-02-16
US11136352B2 (en)	2021-10-05
RS60385B1 (sr)	2020-07-31
CA2936870C (en)	2019-11-26
PT3120868T (pt)	2020-07-16
JP5883476B2 (ja)	2016-03-15
JP2016145210A (ja)	2016-08-12
HK1161106A1 (en)	2012-08-24
SI2331118T1 (sl)	2017-01-31
US20130309193A1 (en)	2013-11-21
HUE049366T2 (hu)	2020-09-28
US20100158931A1 (en)	2010-06-24
US10100085B2 (en)	2018-10-16
US20110002963A1 (en)	2011-01-06
US20210238227A1 (en)	2021-08-05
MX2011003540A (es)	2011-06-20
SI2341927T1 (sl)	2016-08-31
UA125277C2 (uk)	2022-02-16
PL3106175T3 (pl)	2020-08-24
HUE051030T2 (hu)	2021-01-28
DK2172212T3 (da)	2016-12-19
US20160376314A1 (en)	2016-12-29
PT2172212T (pt)	2016-12-22
PL2172211T3 (pl)	2015-05-29
EP2331118A1 (en)	2011-06-15
SI3124043T1 (sl)	2020-07-31
PL3111952T3 (pl)	2019-04-30
US20160376316A1 (en)	2016-12-29
CA2936869A1 (en)	2010-04-08
LT3120869T (lt)	2020-11-10
EP3120870B1 (en)	2020-04-01
JP2014239681A (ja)	2014-12-25
HRP20161504T1 (hr)	2016-12-30
AU2009300088B2 (en)	2014-09-04
BRPI0920759A2 (pt)	2016-03-08
CY1122677T1 (el)	2021-03-12
PT3106175T (pt)	2020-07-01
US8895514B2 (en)	2014-11-25
PT3132801T (pt)	2020-02-04
LT3106175T (lt)	2020-08-10
EP3124043A1 (en)	2017-02-01
JP5855940B2 (ja)	2016-02-09
MX338294B (es)	2016-04-11
EA032437B1 (ru)	2019-05-31
US8961985B2 (en)	2015-02-24
HUE049364T2 (hu)	2020-09-28
PL2172212T3 (pl)	2017-04-28
RS55531B1 (sr)	2017-05-31
HUE031030T2 (en)	2017-06-28
HUE029360T2 (en)	2017-02-28
US20160376315A1 (en)	2016-12-29
CY1116302T1 (el)	2017-02-08
CY1122913T1 (el)	2021-10-29
LT3132801T (lt)	2020-02-10
PT3120870T (pt)	2020-07-01
KR102133402B1 (ko)	2020-07-14
HUE047365T2 (hu)	2020-04-28
CY1119744T1 (el)	2018-06-27
BRPI0920791A2 (pt)	2019-12-10
CY1123526T1 (el)	2022-03-24
PT3069728T (pt)	2019-02-13
US10047124B2 (en)	2018-08-14
HRP20201015T1 (hr)	2020-10-16
EP2172212B1 (en)	2016-10-05
ES2819244T3 (es)	2021-04-15
US20210261614A1 (en)	2021-08-26
SI3120869T1 (sl)	2020-10-30
KR20110082155A (ko)	2011-07-18
LT3120868T (lt)	2020-08-10
HRP20201025T8 (hr)	2022-01-07
US12221493B2 (en)	2025-02-11
EP3120869B1 (en)	2020-07-22
HUE030296T2 (en)	2017-04-28
CY1123113T1 (el)	2021-10-29
WO2010037514A3 (en)	2010-06-03
NZ624533A (en)	2015-09-25
JP2017018102A (ja)	2017-01-26
NZ603016A (en)	2014-05-30
AU2009300087B2 (en)	2014-09-04
JP2017029135A (ja)	2017-02-09
DK3120870T3 (da)	2020-06-22
SI3132801T1 (sl)	2020-03-31
US20160376313A1 (en)	2016-12-29
US10919931B2 (en)	2021-02-16
TR201900852T4 (tr)	2019-02-21
EP2331118B1 (en)	2016-10-26
DK3132801T3 (da)	2020-02-10
PT3124043T (pt)	2020-05-12
DK3111952T3 (en)	2019-01-28
US10941181B2 (en)	2021-03-09
CA2936868A1 (en)	2010-04-08
HRP20200722T1 (hr)	2020-10-16
EA201401104A1 (ru)	2015-05-29
RS60381B1 (sr)	2020-07-31
US20130004456A1 (en)	2013-01-03
JP2016047825A (ja)	2016-04-07
EP3120868A1 (en)	2017-01-25
ES2710608T3 (es)	2019-04-26
DK2331118T3 (da)	2017-01-09
US20160355550A1 (en)	2016-12-08
CA2739387A1 (en)	2010-04-08
KR20180088494A (ko)	2018-08-03
CY1118702T1 (el)	2017-07-12
NZ591882A (en)	2012-12-21
US10047123B2 (en)	2018-08-14
JP5753783B2 (ja)	2015-07-22
ES2804723T3 (es)	2021-02-09
CA2739387C (en)	2019-10-29
KR101756488B1 (ko)	2017-07-11
CA2739384C (en)	2017-05-02
DK3069728T3 (en)	2019-02-25
ES2788129T3 (es)	2020-10-20
HRP20201025T1 (hr)	2020-12-25
PL3120870T3 (pl)	2020-07-27
SI3111952T1 (sl)	2019-01-31
US8119139B2 (en)	2012-02-21
JP2012504393A (ja)	2012-02-23
EP3111952A1 (en)	2017-01-04
EP3132801B1 (en)	2019-10-30
HRP20160915T1 (hr)	2016-10-07
KR102392070B1 (ko)	2022-04-29
HUE042115T2 (hu)	2019-06-28
DK3120868T3 (da)	2020-06-22
JP6294913B2 (ja)	2018-03-14
KR101687840B1 (ko)	2016-12-19
LT3120870T (lt)	2020-08-10
SI2172211T1 (sl)	2015-03-31
SI3120870T1 (sl)	2020-08-31
RS53782B1 (sr)	2015-06-30
WO2010037513A1 (en)	2010-04-08
ES2802227T3 (es)	2021-01-18
PL3132801T3 (pl)	2020-06-15
DK2341927T3 (en)	2016-08-15
ES2788129T8 (es)	2020-11-04
HRP20201228T1 (hr)	2021-02-05
NZ591855A (en)	2012-11-30
EA023013B1 (ru)	2016-04-29
PT2341927T (pt)	2016-08-02
DK2331118T5 (en)	2017-06-19
ES2802226T3 (es)	2021-01-18
US20210347822A1 (en)	2021-11-11
AU2009300087A1 (en)	2010-04-08
EP3132801A1 (en)	2017-02-22
CA2936924A1 (en)	2010-04-08
EA201100586A1 (ru)	2011-10-31
DK3124043T3 (da)	2020-05-04
PT3120869T (pt)	2020-09-22
EP3069728A1 (en)	2016-09-21
ES2708654T3 (es)	2019-04-10
EP2172211B1 (en)	2014-12-03
WO2010037514A2 (en)	2010-04-08
JP6150859B2 (ja)	2017-06-21
CA2936920C (en)	2019-12-03
US20170326217A1 (en)	2017-11-16
US12234298B2 (en)	2025-02-25
SI3120868T1 (sl)	2020-08-31
JP2017000148A (ja)	2017-01-05
SI2172212T1 (sl)	2016-12-30
KR20110074894A (ko)	2011-07-04
JP2017018101A (ja)	2017-01-26
PT3111952T (pt)	2019-02-05
RS60006B1 (sr)	2020-04-30
RS60656B1 (sr)	2020-09-30
CN102170900A (zh)	2011-08-31
MX2011003539A (es)	2011-06-20
PL3120868T3 (pl)	2020-08-24
PL2341927T3 (pl)	2016-11-30
HRP20182151T1 (hr)	2019-02-08
ES2584245T3 (es)	2016-09-26
HRP20150223T8 (hr)	2015-07-03
LT3111952T (lt)	2018-12-27
EP2341927B1 (en)	2016-05-04
JP6367266B2 (ja)	2018-08-01
US20120141517A1 (en)	2012-06-07
CY1121258T1 (el)	2020-05-29
PL3069728T3 (pl)	2019-05-31
PL3120869T3 (pl)	2021-01-25
HUE041446T2 (hu)	2019-05-28
JP6294914B2 (ja)	2018-03-14
CY1123098T1 (el)	2021-10-29
LT3069728T (lt)	2019-02-11
LT2331118T (lt)	2016-12-27
JP2017023136A (ja)	2017-02-02
EP2172212A3 (en)	2010-04-14
RS60338B1 (sr)	2020-07-31
US8318677B2 (en)	2012-11-27
CA2936870A1 (en)	2010-04-08
HRP20200988T1 (hr)	2020-10-16
UA110599C2 (uk)	2016-01-25
ES2770090T3 (es)	2020-06-30
CA2936982A1 (en)	2010-04-08
US9993540B2 (en)	2018-06-12
PT2331118T (pt)	2017-02-06
PL3124043T3 (pl)	2020-07-27
US8653035B2 (en)	2014-02-18
HRP20150223T1 (hr)	2015-06-05
KR20160103558A (ko)	2016-09-01
EP3106175A1 (en)	2016-12-21
ES2612466T3 (es)	2017-05-17
TR201900809T4 (tr)	2019-02-21
UA103202C2 (ru)	2013-09-25
CY1123089T1 (el)	2021-10-29
EP3069728B1 (en)	2018-11-14
EP3120868B1 (en)	2020-04-08
RS58443B1 (sr)	2019-04-30
US20160376317A1 (en)	2016-12-29
CA2936868C (en)	2019-10-22
PT2172211E (pt)	2015-03-09
KR20220058655A (ko)	2022-05-09
CA2739384A1 (en)	2010-04-08
CA2936920A1 (en)	2010-04-08
EP2172211A1 (en)	2010-04-07
US20210253637A1 (en)	2021-08-19
KR20200085381A (ko)	2020-07-14
CN106986919A (zh)	2017-07-28
US10906936B2 (en)	2021-02-02
US20190010190A1 (en)	2019-01-10
RS60386B1 (sr)	2020-07-31
EP2172212A2 (en)	2010-04-07
EP3120870A1 (en)	2017-01-25
JP6297632B2 (ja)	2018-03-20
CA2936869C (en)	2019-08-06
EP3120869A1 (en)	2017-01-25
EA023378B1 (ru)	2016-05-31
EA201100587A1 (ru)	2011-10-31
EP2341927A2 (en)	2011-07-13
CN102170901A (zh)	2011-08-31
BRPI0920791B1 (pt)	2022-01-18
CA2936924C (en)	2019-07-16
RS58229B1 (sr)	2019-03-29
US10227381B2 (en)	2019-03-12
ES2536465T3 (es)	2015-05-25
LT3124043T (lt)	2020-07-10
US20160376312A1 (en)	2016-12-29
CN102170900B (zh)	2016-10-26
US11208434B2 (en)	2021-12-28

Publication	Publication Date	Title
PL2331118T3 (pl)	2017-05-31	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL2567707T3 (pl)	2017-03-31	Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
CY2017019I2 (el)	2018-01-10	Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
IL236516B (en)	2018-05-31	Antibodies and compositions comprising them for treatment of cancer
LT2478907T (lt)	2021-06-25	Kompozicijos vėžiui gydyti
HUE049886T2 (hu)	2020-10-28	Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
ME01814B (me)	2014-09-20	Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
PL3363456T3 (pl)	2021-05-04	Nowa immunoterapia względem wielu nowotworów, w tym raka układu trawiennego i raka żołądka
IL220386B (en)	2020-04-30	Compositions for the liquidation of tumors and uses thereof
DK3401334T5 (da)	2024-09-23	Monoklonale antistoffer mod claudin-18 til cancerbehandling
IL212633A (en)	2015-03-31	A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
HRP20151135T4 (hr)	2019-03-08	Novi i snažni peptidi mhc klase ii dobiveni od survivina
IL213070A0 (en)	2011-07-31	Methods for the treatment of infections and tumors
DK1868579T3 (da)	2011-01-10	Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
ZA201102969B (en)	2011-12-28	Anti cxcr4 antibodies and their use for the treatment of cancer
BRPI0921699A2 (pt)	2016-02-16	complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
PL3443957T3 (pl)	2021-05-04	Związki i kompozycje stosowane w leczeniu nowotworów
HUE047767T2 (hu)	2020-05-28	Macitentánt tartalmazó terápiás készítmények
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EP2328604A4 (en)	2012-03-14	USE OF WNT5-A PEPTIDE DERIVATIVES FOR THE TREATMENT OF MELANOMA AND MAGIC CARCINOMA
BRPI0720323A2 (pt)	2016-08-09	composto, método de tratamento, composição farmacêutica e uso do composto
HRP20181178T1 (hr)	2018-12-14	Anti-androgeni peptidi i njihova uporaba za terapiju raka